Late-stage asset LCM strategy

A top biopharma had just acquired a late-stage asset whose target reached well beyond the lead indication and needed to know fast which expansion bets were worth funding.

C558-96

Full indication universe screened against agreed criteria

Situation

Need for LCM roadmap

Top biopharma had recently made a high-profile acquisition of late-stage clinical asset with a target with broad potential in other indications.
Executive team sought rapid development of an LCM plan, with emphasis on additional indications and alternative formulations.
Client sought collaborative process to identify and assess opportunities, followed by a rigorous business case evaluation of lead contenders.

Project

Indication screening and business cases

First phase of opportunity identification involved synthesizing input multiple TA leaders and internal SMEs, and validate via external scientific and market research, culminating in a prioritization.
Second phase was a deep-dive business case evaluation of top 3 indications, with facilitation of internally-driven clinical planning, coupled with externally-oriented product profile evaluation via market interviews, competitor/market analysis and financial modeling.

Clinical, market and financial deep-dives on finalists

Probabilistic NPV scenarios framed the committee decision

Outcome

Aligned investment path

Identified lead indications for LCM investment, which was different than in-going momentum case.
Developed full rationale and materials for executive committee review, leading to an aligned path forward.

MORE CASE STUDIES

Related work

Institutional

Strategy for Statewide Health Information Exchange

A non-profit health information exchange was facing financial struggles and needed a new strategy that would keep it financially sustainable

HIE, Health IT,

Medtech, Early Stage

Growth strategy for point-of-care testing

Post pandemic an innovative diagnostics platform company wanted to dramatically increase its market by targeting retail clinics for its point-of-care diagnostics platform

Growth, product market fit, value proposition

Institutional

University Trials

Large university wanting to dramatically increase its clinical research footprint